TNFSF13B and systemic lupus erythematosus: Recent developments in B cell-targeting immunotherapies, such as monoclonal antibodies (mAb) against CD20 and B cell activating factor (BAFF), have shown promise in managing severe and drug-refractory SLE (25, 26).